Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Next Previous
X
Search
Trial Profile

Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Feb 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pralatrexate (Primary) ; Cobalamin; Folic acid
  • Indications Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Mundipharma International

    • Most Recent Events

    • 14 Dec 2021 Results of efficacy and safety of pralatrexate by using data from four trials including this trial presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 01 Oct 2017 Results assessing the efficacy of pralatrexate in patients with T-cell lymphoma, were published in the Cancer Science.
    • 01 Oct 2017 Status changed from active, no longer recruiting to completed, according to results published in the Cancer Science.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top